ARTICLE | Strategy
Amgen's heart start
How Amgen plans to build its CV footprint with heart failure drug Corlanor
April 27, 2015 7:00 AM UTC
Amgen Inc.'s new heart failure drug Corlanor ivabradine, the company's first CV product, will serve as a launchpad for its other cardiovascular candidates, including PCSK9 inhibitor Repatha evolocumab.
FDA approved Corlanor on April 15 to treat patients with chronic heart failure who are on maximally tolerated doses of beta blockers but still have a resting heart rate of at least 70 bpm or have contraindications to beta blockers...